登录 查看组织和合同定价。
选择尺寸
关于此项目
UNSPSC Code:
41106514
Biological source:
human unknown/unspecified
Relevant disease(s):
cancer
Growth mode:
Suspension
Karyotype:
46,XX,-8,+t(3;8)(p12-13;q12),t(11;14)(q13;q32)
Morphology:
Lymphoblastoid
biological source
human unknown/unspecified
packaging
tube of 5 μg 96090515-DNA-5UG, pkg of vial of cells 96090515-1VL
growth mode
Suspension
karyotype
46,XX,-8,+t(3;8)(p12-13;q12),t(11;14)(q13;q32)
morphology
Lymphoblastoid
products
Not specified
receptors
Not specified
technique(s)
cell culture | mammalian: suitable
relevant disease(s)
cancer
shipped in
dry ice
storage temp.
−196°C
Application
Ig expression of neoplastic cells
Biochem/physiol Actions
Human Caucasian B-prolymphocytic leukaemia, EBV-transformed
JVM-2 has been derived from EBV and TPA treated mononuclear cells from a 63 year old female patient with B-prolymphocytic leukaemia. Thirty-three percent of cells were shown to be positive for surface lambda light chain, 37% for IgA, 29% for IgG and 3% for IgM and IgD. In addition, 50% were found to express cytoplasmic IgM and lambda light chain. Expression of the following leukocyte differentiation antigens was found: CD9, CD19, CD20, CD23, CD24, MA6, CD37, CD38, FMC1, FMC7, MHC Class I, FMC16, MHC Class II DR/DP/DQ. The immunoglobulin heavy-and light-chain genes showed the same pattern of rearrangement as in the original prolymphocytes. The cells are lymphoblastoid with large floating aggregates present. The cell line has been eradicated from mycoplasma at ECACC.
STR-PCR Data: Amelogenin: X
CSF1PO: 11
D13S317: 11,13
D16S539: 12,13
D5S818: 11,12
D7S820: 10,11
THO1: 6,9
TPOX: 8,11
vWA: 17
CSF1PO: 11
D13S317: 11,13
D16S539: 12,13
D5S818: 11,12
D7S820: 10,11
THO1: 6,9
TPOX: 8,11
vWA: 17
Preparation Note
Maintain cultures between 3-9 x 100,000/ml; 5% CO2; 37°C.
RPMI 1640 +2mM Glutamine + 10% Foetal Bovine Serum (FBS).
Other Notes
Additional freight & handling charges may be applicable for Asia-Pacific shipments. Please check with your local Customer Service representative for more information.
法规信息
常规特殊物品
低风险生物材料
此项目有
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持